Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184
Lantern Pharma has won a trio of rare-pediatric-disease designations from the Food and Drug Administration for its investigational drug candidate LP-184 in multiple ultra-rare children's cancers.
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP ...
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer ...
Business Insider11 小时
Lantern Pharma Says FDA Oks Rare Pediatric Disease Designations In MRT, RMS, And Hepatoblastoma
Lantern was granted these rare pediatric disease designations in: malignant rhabdoid tumors (MRT), rhabdomyosarcoma (RMS), and hepatoblastoma. Lantern's investigational drug candidate, LP-184, has ...
WYFF11 天
Childhood cancer awareness: An Upstate mom’s journey through her daughter's cancer
THEY TOLD ME THAT THEY FOUND A LESIONS ON HER LIVER. THEY THEN WENT TO MUSK IN CHARLESTON, WHERE THEY DIAGNOSED KYLIE WITH ...
WYFF 4 Greenville-Spartanburg on MSN11 天
An Upstate mom’s journey through her daughter's cancer
An Upstate mom shares the uphill battle to recovery from her daughter's cancer and is grateful for where they are now. Kylie Jeter, 3, is an energetic little girl, but just a few years ago, it was a ...
Medscape21 天
The Comparison of Grey-scale Ultrasonic and Clinical Features of Hepatoblastoma and ...
Hua Zhuang; Yu-lan Peng; Tian-wu Chen; Yong Jiang; Yan Luo; Qiong Zhang; Zhi-gang Yang ...
Medscape27 天
The Comparison of Grey-scale Ultrasonic and Clinical Features of Hepatoblastoma and ...
Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...